Biogen Idec

Biogen ventures into ophthalmology with $1-bn AGTC tie-up

04 Jul 2015

The collaboration will focus on the development of a portfolio of therapeutic programmes for orphan diseases of the retina that can lead to blindness in children and adults

Biogen Idec to pay Elan Corp $3.25 bn plus for full rights of multiple sclerosis drug Tysabri

06 Feb 2013

Biogen assumes full development responsibilities for hemophilia therapy

18 Feb 2010

Facet Biotech spurns Biogen’s buyout bid

09 Sep 2009

Biogen Idec up for sale after Icahn offer

By Our Corporate Bureau | 13 Oct 2007

Nicholas Piramal enters into alliance with Biogen Idec, USA

By Mumbai: | 02 Dec 2003